GeneDx Holdings Falls 25% in Four Weeks While EPS Estimates Rise 29.3%
GeneDx Holdings has fallen 25.1% over the past four weeks, pushing its RSI to 29.87 and into oversold territory. Meanwhile, analysts have raised 2026 EPS estimates by 29.3% over the last 30 days, and the stock earned a Strong Buy ranking based on EPS revision trends.
1. Recent Price Decline
GeneDx Holdings shares have declined 25.1% over the past four weeks due to sustained selling pressure, driving the stock well below recent trading levels.
2. Oversold Technical Signal
The stock’s Relative Strength Index has fallen to 29.87, a level commonly viewed as oversold and suggestive of a potential price reversal when selling exhaustion occurs.
3. Analyst EPS Revisions
Over the last 30 days, consensus 2026 EPS estimates for GeneDx have increased by 29.3%, reflecting growing confidence in the company’s upcoming earnings performance.
4. Strong Buy Ranking Implications
The stock secured a Strong Buy ranking in a model tracking EPS revision trends, indicating top‐tier positioning among over 4,000 stocks and supporting a case for near‐term upside.